Alps Advisors Inc Aerovate Therapeutics, Inc. Transaction History

Alps Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$17.68 - $29.57 $14,161 - $23,685	801 Added 4.28%	19,519 $577,000
Q4 2023 Feb 14, 2024	SELL	$9.58 - $24.25 $16,065 - $40,667	-1,677 Reduced 8.22%	18,718 $423,000
Q3 2023 Nov 14, 2023	BUY	$12.9 - $18.88 $26,767 - $39,176	2,075 Added 11.33%	20,395 $276,000
Q2 2023 Aug 14, 2023	BUY	$15.63 - $22.01 $33,010 - $46,485	2,112 Added 13.03%	18,320 $314,000
Q1 2023 May 10, 2023	SELL	$19.17 - $27.7 $9,144 - $13,212	-477 Reduced 2.86%	16,208 $326,000
Q4 2022 Feb 14, 2023	BUY	$15.92 - $30.52 $265,625 - $509,226	16,685 New	16,685 $488,000

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $63.6M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.